spawns
Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE:PFE) announced plans to discontinue its once-daily oral obesity drug, danuglipron.
Other notable gainers included Terns Pharmaceuticals (TERN